Researchers at the University of Oxford led by Professor Sarah Gilbert are investigating how a recombinant virus, specifically a chimp adenovirus, can be used to potentially vaccinate against the SARS-CoV-2 virus in humans. People are currently being recruited for the next phase of human clinical trials. By introducing and maintaining the spike protein concentrations into patients, healthcare professionals will be able to induce an immune response and hopefully help the body’s immune system create antibodies that are effective at preventing COVID-19.
Read more:
